Estudios

Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med Vol 203, Iss 4, pp 484–492, Feb 15, 2021 Conclusions: A majority of patients with PAH still insufficiently improved after 6 months of initial combinations of oral drugs is identifiable at initial evaluation by hemodynamic response criteria added to risk scores.

Presentará el Dr. Marco Ayala

03 de enero 2024 16:00hrs / 17:15hrs

The Effect of Inhaled Corticosteroids on Pneumonia Risk in Patients With COPD-Bronchiectasis Overlap. A UK Population-Based Case-Control Study. CHEST 2023; 164(4):875-884 INTERPRETATION: ICS use does not augment further the already increased risk of hospitalisation for pneumonia associated with concomitant bronchiectasis in patients with COPD.

Presentará la Dra. Macarena Lagos

27 de diciembre 2023 16:00hrs / 17:15hrs

Lifestyle, Genetic Susceptibility, and the Risk of Idiopathic Pulmonary Fibrosis. A Large Prospective Cohort Study. CHEST 2023; 164(4):929-938 INTERPRETATION: Exposure to unfavorable lifestyle significantly increased the risk of IPF, particularly in those with high genetic risk.

Presentará el Dr. Francisco Osses

20 de diciembre 2023 16:00hrs / 17:15hrs

Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD. A Randomized Clinical Trial. Am J Respir Crit Care Med Vol 206, Iss 11, pp 1326–1335, Dec 1, 202 A high-flow nasal cannula is a reasonable therapeutic option for patients with stable hypercapnic chronic obstructive pulmonary disease and a history of exacerbations.

Presentará el Dr. Felipe Rozas

13 de diciembre 2023 16:00hrs / 17:15hrs

Inhaled Amikacin to Prevent Ventilator-Associated Pneumonia. DOI: 10.1056/NEJMoa2310307 Among patients who had undergone mechanical ventilation for at least 3 days, a subsequent 3-day course of inhaled amikacin reduced the burden of ventilator associated pneumonia during 28 days of follow-up.

Presentará el Dr. Jonathan Azolas

06 de diciembre 2023 16:00hrs / 17:15hrs